News >

Mittendorf Explains Growing Role of Checkpoint Inhibitors in Breast Cancer

Laura Panjwani
Published: Monday, Mar 21, 2016

Dr. Elizabeth A. Mittendorf

Elizabeth A. Mittendorf, MD, PhD

There is still a lot to be learned regarding the use of checkpoint inhibitors in breast cancer, but the field is advancing rapidly. Several agents have shown potential in recent trials.

, Mittendorf talked about checkpoint inhibition studies in TNBC, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.

OncLive: How has the use of checkpoint inhibition in breast cancer evolved in the past year?

Mittendorf: We have additional data now for multiple agents in TNBC; this time last year we just had pembrolizumab.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x